A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

Summary

This study will evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of CBP-201 in adult subjects with moderate to severe atopic dermatitis.

Timeline

Start

2020-07-17

Primary completion

2021-07-28

Completion

2021-09-22

Outcome

Met primary endpoint

registry analysis (superiority test); CBP-201 300 Q2W vs Placebo; p = 0.0007; Mean Difference (Final Values) 23.36; ANCOVA NCT04444752 ↗

registry analysis (superiority test); CBP-201 150 Q2W vs Placebo; p = 0.0067; Mean Difference (Final Values) 17.89; ANCOVA. NCT04444752 ↗

registry analysis (superiority test); CBP-201 300 Q4W vs Placebo; p = 0.0004; Mean Difference (Final Values) 23.83; ANCOVA. NCT04444752 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CBP-201	Unknown	—	Subcutaneous

Indications